The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Zymeworks BC Inc (NASDAQ: ZYME) closed at $25.48 in the last session, up 2.17% from day before closing price of $24.94. In other words, the price has increased by $2.17 from its previous closing price. On the day, 0.66 million shares were traded. ZYME stock price reached its highest trading level at $26.46 during the session, while it also had its lowest trading level at $25.44.
Ratios:
We take a closer look at ZYME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 03, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $32.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 24 ’25 when Derek John Michael Miller bought 118,000 shares for $23.82 per share.
Neil Gallagher bought 105,000 shares of ZYME for $2,501,100 on Nov 21 ’25. On May 15 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 49,502 shares for $11.43 each. As a result, the insider paid 565,847 and bolstered with 17,877,989 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1929737600 and an Enterprise Value of 1673805824. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.29 while its Price-to-Book (P/B) ratio in mrq is 6.03. Its current Enterprise Value per Revenue stands at 12.446 whereas that against EBITDA is -27.452.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.30, which has changed by 0.8111837 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $28.49, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is 22.11%, while the 200-Day Moving Average is calculated to be 69.52%.
Shares Statistics:
According to the various share statistics, ZYME traded on average about 1.13M shares per day over the past 3-months and 711180 shares per day over the past 10 days. A total of 75.14M shares are outstanding, with a floating share count of 72.91M. Insiders hold about 3.31% of the company’s shares, while institutions hold 99.50% stake in the company. Shares short for ZYME as of 1764288000 were 5609170 with a Short Ratio of 4.97, compared to 1761868800 on 7531090. Therefore, it implies a Short% of Shares Outstanding of 5609170 and a Short% of Float of 10.9799996.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 10.0 analysts currently analyzing and rating the stock of Zymeworks BC Inc (ZYME).The consensus estimate for the next quarter is -$0.09, with high estimates of $0.55 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.13 and -$1.25 for the fiscal current year, implying an average EPS of -$0.87. EPS for the following year is $0.27, with 11.0 analysts recommending between $3.76 and -$1.52.
Revenue Estimates
According to 9 analysts,. The current quarter’s revenue is expected to be $21.21M. It ranges from a high estimate of $59M to a low estimate of $1.2M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $31.03MFor the next quarter, 9 analysts are estimating revenue of $24.2M. There is a high estimate of $29.8M for the next quarter, whereas the lowest estimate is $14.58M.
A total of 11 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $162.09M, while the lowest revenue estimate was $104.5M, resulting in an average revenue estimate of $124.33M. In the same quarter a year ago, actual revenue was $76.3MBased on 11 analysts’ estimates, the company’s revenue will be $246.12M in the next fiscal year. The high estimate is $502.1M and the low estimate is $96.08M.
